Scans

Tools

Home

Charts

Watchlist

Products

Amines & Plasticizers Ltd

AMNPLST

NSE

₹160.39-2.38%19 Oct 2026

Reports

Specialty Chemicals

Amines & Plasticizers Ltd

AMNPLST

NSE

₹160.39

-2.38%

19 Oct 2026

SOICxStockScans Reports

Ask AI

Specialty Chemicals

Indices

Business Overview: What the company does, in plain English.Growth Catalysts: The forward growth drivers and triggers.Forensic Report: Accounting quality and red flags.Deep Dive Report: In-depth business analysis.

Amines & Plasticizers Ltd is a speciality chemicals maker whose products are the invisible workhorses inside oil refineries, pharmaceutical plants, textile mills, and electronics factories - the amines and solvents that strip out impurities, catalyse reactions, and make fibres possible. Founded in 1973 as a first-generation venture by Hemant Kumar Ruia, it was the first Indian company to indigenously develop methyl diethanolamine (MDEA), a critical gas-treating solvent, and has since grown into one of the world’s largest producers of N-methyl morpholine oxide (NMMO), serving customers across more than 85 countries. The recurring approach is to build proprietary, hard-to-copy chemical know-how in-house - for every product except ethanolamines, the technology comes from its own R&D - and then sell those molecules globally into industries where switching suppliers is slow and expensive.

Business segments

Four chemical engines built on a single manufacturing backbone - a gas-treating franchise that cleans the world’s refineries, an ethanolamine business that dominates its home market, a morpholine platform that enables greener textiles, and a specialty ethoxylates engine feeding everything from cosmetics to electronics - plus a small oilfield-and-engineering division that rounds out the portfolio.

1. Gas treating chemicals and specialty solvents: the refinery’s cleaning crew

APL makes the solvents that strip carbon dioxide and hydrogen sulphide out of gas streams in refineries, fertiliser plants, and hydrogen production units - and it was the first Indian company to do so with its own technology.

The cornerstone molecule - MDEA is the base solvent for removing CO₂ and H₂S from process gas, and APL’s indigenously developed version anchors a family of formulated blends sold under the Aminosol brand.
Custom blends for specific customers - the company has developed tailor-made solvent formulations for over 25 domestic and international clients, including demulsifiers matched to country-specific crude profiles and carbon-capture formulations for flue gas and cement plants.
Not just chemicals, but the engineering to use them - APL sells analytical and process engineering services alongside its solvents, including amine analysis, process simulation software, operator training, and even physical Amine Reclamation Units that extend solvent life inside refineries.
Hydrogen and carbon capture are the next frontier - its formulated MDEA already works across Brown, Grey, Blue, and Turquoise hydrogen production, and the company has tied up with a leading Japanese multinational to manufacture new carbon-capture solvents.

2. Alkanolamines and alkyl alkanolamines: the domestic champion

APL supplies roughly 70% of India’s ethanolamine demand - the nitrogen-containing alcohols that go into everything from cement additives and water-treatment chemicals to pharmaceutical raw materials.

A commanding home-market position - the company holds a 75-80% domestic market share in ethanolamines and caters to approximately 70% of total Indian demand for ethanolamines and alkyl alkanolamines.
Products that touch construction and medicine - two propylene-oxide-based alkyl alkanolamines are used as cement grinding aids in infrastructure, while another product gained prominence as a raw material for COVID-19 treatment drugs.
Green-chemistry credentials in paints - two products developed by the company are used in water-borne paints and automobile coatings, replacing environmentally unfriendly solvents.
The building blocks for multiple industries - these molecules feed into oil refining, petrochemicals, pharmaceuticals, agrochemicals, and textiles, making them a broad-spectrum intermediate.

3. Morpholine and derivatives: the green-textile enabler

APL is among the world’s largest producers of NMMO, the solvent that makes Lyocell fibre possible - a cleaner alternative to viscose that has reshaped the textile industry.

The molecule behind a fibre revolution - NMMO (N-Methylmorpholine N-oxide) is an environment-friendly solvent that dissolves wood pulp to spin Lyocell fibre, replacing the polluting viscose process without environmental harm.
Global scale in a niche - the company is recognised among the world’s leading manufacturers of morpholine and its derivatives, and ranks among the largest producers of NMMO globally.
Pharmaceutical linkages - one morpholine derivative serves as a key raw material for an immunosuppressant drug, giving the engine exposure to high-value pharma supply chains.
A natural hedge against raw-material risk - the company imports morpholine as a raw material but exports morpholine derivatives, so foreign-exchange exposure is largely offset by the export revenue stream.

4. EO/PO-based specialty products: the formulation toolkit

Using ethylene oxide and propylene oxide as building blocks, APL makes ethoxylates, polyols, and copolymers that become surfactants, polyurethane systems, and performance additives for a widening set of end markets.

Surfactants and emulsifiers - alcohol ethoxylates, sorbitol ethoxylates, and fatty alcohol propoxylates feed the growing surfactants field, while neem-based agrochemical emulsifiers contribute to green chemistry.
Polyols for polyurethanes - glycerol polyol and PPG 4000 are the precursors for polyurethane systems used in foams, coatings, and elastomers.
High-purity grades for demanding applications - demand is rising for high-purity versions of cosmetic ingredients, metal-working fluids, drug intermediates, textile auxiliaries, and electronic chemicals, all of which draw on EO/PO chemistry.
R&D is expanding the range - the company has commercialised cocoamine-based ethoxylates and glycerin-based propoxylates through in-house R&D, and is designing a range of surfactants based on tridecyl alcohol ethoxylate.

5. Oilfield chemicals, industrial gases, and engineering services: the ancillary workshop

A compact division that supplies hydrogen-sulphide scavengers and corrosion inhibitors to upstream oil and gas, plus dissolved acetylene and custom pressure equipment from a separate site at Khopoli.

Chemicals for the oil patch - the portfolio includes H₂S scavengers, acid corrosion inhibitors, flow improvers, pour-point depressants, bactericides, and oil-spill dispersants, with products accepted in international markets.
A small industrial-gas operation - the Khopoli plant manufactures dissolved acetylene with a capacity of 2 lakh cubic metres per year, running at roughly 50% utilisation with a team of eight.
Heavy fabrication on the side - the engineering services division at the same Khopoli site builds heat exchangers, pressure vessels, and boilers with a capacity of 100 tonnes per month and a team of 80.
Molecular-sieve distribution - APL represents one of the world’s biggest molecular-sieve producers and is a major distributor in India, supplying drying agents used in industrial gases, fuel ethanol, and polymer processing.

Manufacturing, technology, and R&D infrastructure

Two integrated plants in Maharashtra, 13 reaction chemistries under one roof, and a DSIR-recognised R&D lab that has commercialised 43 new products in five years - this is the shared backbone that makes every segment possible.

Two sites, one chemistry backbone - the main Turbhe plant in Navi Mumbai sits on 18.11 acres with 32,760 MTPA of installed capacity and runs at 85% utilisation, while the Khopoli site adds another 25.41 acres housing the gases and engineering divisions.
In-house R&D as the growth engine - the DSIR-recognised lab has commercialised 43 new products over five years, developed import-substitute molecules for electric-vehicle batteries and hydrogen electrolysers, and created custom solvent formulations for more than 25 customers.
Self-sufficient engineering - an in-house engineering division handles plant maintenance and equipment upkeep, reducing reliance on outside contractors and keeping costs down.
Raw-material strategy built around ethylene oxide - the single most important feedstock is ethylene oxide, sourced locally because it is too inflammable to import; the company manages price volatility through commercial negotiation and has invested in its own fleet of EO tanks for safer logistics.

Group structure and partners

A lean structure centred on a single listed entity with one overseas subsidiary in the UAE, a 26% stake in a captive solar-power venture, and technology partnerships with American and Japanese multinationals.

The UAE subsidiary - wholly owned Amines and Plasticizers FZ-LLC in the Ras Al Khaimah Free Trade Zone trades in the company’s products and those of other manufacturers, giving APL a foothold in Middle Eastern markets.
Captive solar power - a 26% stake in Radiance MH Sunrise Six Private Limited was taken as a regulatory pre-condition to secure a 2.6 MW ground-mounted solar plant that supplies concessional green power to the company’s operations.
Global technology tie-ups - the company has memoranda of understanding with leading American and Japanese corporations for customised product development, including a tie-up with a Japanese multinational for manufacturing new carbon-capture solvents.
Promoter-led governance - the board is chaired by founder Hemant Kumar Ruia (over four decades of experience) alongside his son Yashvardhan Ruia as Executive Director; the company is listed on both BSE and NSE.

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison

Price

Charts

Documents

Edit Ratios

Mkt Cap

Market Capitalization

₹882Cr

Close Price

₹160.39

Industry

Specialty Chemicals

Price To Earnings

22.88

Price To Sales

1.52

Revenue

₹581Cr

Rev Gr TTM

Revenue Growth TTM

-12.40%

PAT Gr TTM

PAT Growth TTM

-3.04%

Consolidated

Standalone

Numbers

Percentage

Quarter	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue RevenueCr	157	175	177	137	167	191	166	140	133	142	155	151
Growth YoY Revenue Growth YoY%	19.8	9.1	6.3	0.3	5.9	8.8	-6.5	2.0	-20.1	-25.3	-6.4	7.3
Expenses ExpensesCr	141	158	155	123	150	174	145	127	122	130	132	136
Operating Profit Operating ProfitCr	16	17	22	15	16	17	21	13	11	13	23	15
OPM OPM%	10.1	9.7	12.4	10.8	9.8	8.9	12.7	9.3	8.1	8.8	15.1	9.9
Other Income Other IncomeCr	1	1	0	0	0	0	0	0	0	0	0	0
Interest Expense Interest ExpenseCr	4	3	3	2	2	3	3	2	1	1	2	1
Depreciation DepreciationCr	1	1	1	1	1	1	1	1	1	1	1	1
PBT PBTCr	12	13	17	12	13	13	17	10	8	11	21	13
Tax TaxCr	3	4	5	3	3	3	4	3	2	3	5	3
PAT PATCr	9	10	13	9	10	10	13	7	6	8	15	9
Growth YoY PAT Growth YoY%	151.8	100.8	51.4	9.3	7.6	-1.2	-1.0	-14.2	-36.9	-22.3	19.8	27.5
NPM NPM%	5.8	5.6	7.3	6.3	5.9	5.1	7.7	5.3	4.6	5.3	9.9	6.3
EPS EPS₹	1.6	1.8	2.4	1.6	1.8	1.8	2.3	1.4	1.1	1.4	2.8	1.7

Quarter	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue RevenueCr	157	175	177	137	167	191	166	140	133	142	155	151
Growth YoY Revenue Growth YoY%	19.8	9.1	6.3	0.3	5.9	8.8	-6.5	2.0	-20.1	-25.3	-6.4	7.3
Expenses ExpensesCr	141	158	155	123	150	174	145	127	122	130	132	136
Operating Profit Operating ProfitCr	16	17	22	15	16	17	21	13	11	13	23	15
OPM OPM%	10.1	9.7	12.4	10.8	9.8	8.9	12.7	9.3	8.1	8.8	15.1	9.9
Other Income Other IncomeCr	1	1	0	0	0	0	0	0	0	0	0	0
Interest Expense Interest ExpenseCr	4	3	3	2	2	3	3	2	1	1	2	1
Depreciation DepreciationCr	1	1	1	1	1	1	1	1	1	1	1	1
PBT PBTCr	12	13	17	12	13	13	17	10	8	11	21	13
Tax TaxCr	3	4	5	3	3	3	4	3	2	3	5	3
PAT PATCr	9	10	13	9	10	10	13	7	6	8	15	9
Growth YoY PAT Growth YoY%	151.8	100.8	51.4	9.3	7.6	-1.2	-1.0	-14.2	-36.9	-22.3	19.8	27.5
NPM NPM%	5.8	5.6	7.3	6.3	5.9	5.1	7.7	5.3	4.6	5.3	9.9	6.3
EPS EPS₹	1.6	1.8	2.4	1.6	1.8	1.8	2.3	1.4	1.1	1.4	2.8	1.7

Consolidated

Standalone

Numbers

Percentage

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Revenue RevenueCr	262	295	326	455	399	442	563	597	647	661	571	581
Growth Revenue Growth%	-13.1	12.5	10.7	39.4	-12.3	10.7	27.4	6.1	8.3	2.1	-13.6	-12.4
Expenses ExpensesCr	239	267	298	421	357	389	523	555	578	592	511	520
Operating Profit Operating ProfitCr	23	28	28	34	42	53	40	42	69	69	60	62
OPM OPM%	8.9	9.6	8.7	7.4	10.4	11.9	7.1	7.1	10.7	10.4	10.5	10.6
Other Income Other IncomeCr	0	1	4	3	1	5	5	3	3	1	1	1
Interest Expense Interest ExpenseCr	8	6	7	8	9	10	9	10	13	10	5	5
Depreciation DepreciationCr	2	2	3	3	3	4	4	5	5	6	6	6
PBT PBTCr	14	21	23	26	30	44	32	30	54	55	49	52
Tax TaxCr	5	6	8	9	6	11	8	7	14	14	13	14
PAT PATCr	9	15	15	16	25	33	24	23	40	41	37	39
Growth PAT Growth%	44.1	63.6	-0.3	11.3	49.7	32.5	-26.8	-4.1	74.1	3.0	-10.9	-3.0
NPM NPM%	3.5	5.0	4.5	3.6	6.2	7.4	4.2	3.8	6.2	6.2	6.4	6.6
EPS EPS₹	1.6	2.7	2.7	3.0	4.5	5.9	4.3	4.2	7.2	7.5	6.6	7.0

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Revenue RevenueCr	262	295	326	455	399	442	563	597	647	661	571	581
Growth Revenue Growth%	-13.1	12.5	10.7	39.4	-12.3	10.7	27.4	6.1	8.3	2.1	-13.6	-12.4
Expenses ExpensesCr	239	267	298	421	357	389	523	555	578	592	511	520
Operating Profit Operating ProfitCr	23	28	28	34	42	53	40	42	69	69	60	62
OPM OPM%	8.9	9.6	8.7	7.4	10.4	11.9	7.1	7.1	10.7	10.4	10.5	10.6
Other Income Other IncomeCr	0	1	4	3	1	5	5	3	3	1	1	1
Interest Expense Interest ExpenseCr	8	6	7	8	9	10	9	10	13	10	5	5
Depreciation DepreciationCr	2	2	3	3	3	4	4	5	5	6	6	6
PBT PBTCr	14	21	23	26	30	44	32	30	54	55	49	52
Tax TaxCr	5	6	8	9	6	11	8	7	14	14	13	14
PAT PATCr	9	15	15	16	25	33	24	23	40	41	37	39
Growth PAT Growth%	44.1	63.6	-0.3	11.3	49.7	32.5	-26.8	-4.1	74.1	3.0	-10.9	-3.0
NPM NPM%	3.5	5.0	4.5	3.6	6.2	7.4	4.2	3.8	6.2	6.2	6.4	6.6
EPS EPS₹	1.6	2.7	2.7	3.0	4.5	5.9	4.3	4.2	7.2	7.5	6.6	7.0

Consolidated

Standalone

Numbers

Percentage

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital Equity CapitalCr	11	11	11	11	11	11	11	11	11	11	11
Reserves ReservesCr	30	44	57	71	97	130	151	172	209	248	281
Current Liabilities Current LiabilitiesCr	72	79	92	130	88	130	115	131	139	138	109
Non Current Liabilities Non Current LiabilitiesCr	26	27	30	40	35	34	33	31	31	20	20
Total Liabilities Total LiabilitiesCr	140	161	190	252	232	305	310	344	389	416	422
Current Assets Current AssetsCr	91	106	128	174	149	217	220	256	303	332	342
Non Current Assets Non Current AssetsCr	48	55	62	78	83	88	90	88	86	84	81
Total Assets Total AssetsCr	140	161	190	252	232	305	310	344	389	416	422

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital Equity CapitalCr	11	11	11	11	11	11	11	11	11	11	11
Reserves ReservesCr	30	44	57	71	97	130	151	172	209	248	281
Current Liabilities Current LiabilitiesCr	72	79	92	130	88	130	115	131	139	138	109
Non Current Liabilities Non Current LiabilitiesCr	26	27	30	40	35	34	33	31	31	20	20
Total Liabilities Total LiabilitiesCr	140	161	190	252	232	305	310	344	389	416	422
Current Assets Current AssetsCr	91	106	128	174	149	217	220	256	303	332	342
Non Current Assets Non Current AssetsCr	48	55	62	78	83	88	90	88	86	84	81
Total Assets Total AssetsCr	140	161	190	252	232	305	310	344	389	416	422

Consolidated

Standalone

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow Operating Cash FlowCr	14	10	22	10	31	44	-27	5	47	29	66
Investing Cash Flow Investing Cash FlowCr	-1	-5	-4	-16	-17	-6	-4	-2	-1	-3	-1
Financing Cash Flow Financing Cash FlowCr	-13	-5	-14	12	-22	6	-13	0	-16	-20	-58
Net Cash Flow Net Cash FlowCr	-1	0	4	6	-8	44	-43	3	30	6	7
Free Cash Flow Free Cash FlowCr	12	4	14	1	4	33	-35	2	43	26	66
CFO To PAT CFO To PAT%	149.9	64.2	146.5	59.2	125.5	133.5	-111.3	19.8	117.6	71.1	181.8
CFO To EBITDA CFO To EBITDA%	58.3	33.5	76.1	28.7	74.0	82.4	-66.1	10.7	67.8	42.2	111.1

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow Operating Cash FlowCr	14	10	22	10	31	44	-27	5	47	29	66
Investing Cash Flow Investing Cash FlowCr	-1	-5	-4	-16	-17	-6	-4	-2	-1	-3	-1
Financing Cash Flow Financing Cash FlowCr	-13	-5	-14	12	-22	6	-13	0	-16	-20	-58
Net Cash Flow Net Cash FlowCr	-1	0	4	6	-8	44	-43	3	30	6	7
Free Cash Flow Free Cash FlowCr	12	4	14	1	4	33	-35	2	43	26	66
CFO To PAT CFO To PAT%	149.9	64.2	146.5	59.2	125.5	133.5	-111.3	19.8	117.6	71.1	181.8
CFO To EBITDA CFO To EBITDA%	58.3	33.5	76.1	28.7	74.0	82.4	-66.1	10.7	67.8	42.2	111.1

Consolidated

Standalone

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr	92	219	318	183	110	420	601	385	909	1,179	748	882
Price To Earnings Price To Earnings	10.4	14.8	21.6	11.1	4.5	12.9	25.2	16.8	22.8	28.8	20.5	22.9
Price To Sales Price To Sales	0.3	0.7	1.0	0.4	0.3	0.9	1.1	0.6	1.4	1.8	1.3	1.5
Price To Book Price To Book	2.3	4.0	4.7	2.2	1.0	3.0	3.7	2.1	4.1	4.6	2.6	3.0
EV To EBITDA EV To EBITDA	6.3	9.7	12.8	7.2	3.9	8.4	16.6	10.8	13.8	17.5	12.1	14.2
Profitability Ratios Profitability Ratios
GPM GPM%	24.4	27.6	25.0	21.7	25.8	28.1	18.4	18.0	23.4	24.2	23.9	23.9
OPM OPM%	8.9	9.6	8.7	7.4	10.4	11.9	7.1	7.1	10.7	10.4	10.5	10.6
NPM NPM%	3.5	5.0	4.5	3.6	6.2	7.4	4.2	3.8	6.2	6.2	6.4	6.6
ROCE ROCE%	21.9	24.0	24.7	21.4	24.4	25.0	17.5	15.1	21.9	19.3	17.2	17.2
ROE ROE%	22.2	26.7	21.7	20.1	22.8	23.2	14.7	12.5	18.1	15.8	12.5	12.5
ROA ROA%	6.5	9.2	7.8	6.5	10.6	10.7	7.7	6.7	10.2	9.8	8.7	8.7
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr	92	219	318	183	110	420	601	385	909	1,179	748	882
Price To Earnings Price To Earnings	10.4	14.8	21.6	11.1	4.5	12.9	25.2	16.8	22.8	28.8	20.5	22.9
Price To Sales Price To Sales	0.3	0.7	1.0	0.4	0.3	0.9	1.1	0.6	1.4	1.8	1.3	1.5
Price To Book Price To Book	2.3	4.0	4.7	2.2	1.0	3.0	3.7	2.1	4.1	4.6	2.6	3.0
EV To EBITDA EV To EBITDA	6.3	9.7	12.8	7.2	3.9	8.4	16.6	10.8	13.8	17.5	12.1	14.2
Profitability Ratios Profitability Ratios
GPM GPM%	24.4	27.6	25.0	21.7	25.8	28.1	18.4	18.0	23.4	24.2	23.9	23.9
OPM OPM%	8.9	9.6	8.7	7.4	10.4	11.9	7.1	7.1	10.7	10.4	10.5	10.6
NPM NPM%	3.5	5.0	4.5	3.6	6.2	7.4	4.2	3.8	6.2	6.2	6.4	6.6
ROCE ROCE%	21.9	24.0	24.7	21.4	24.4	25.0	17.5	15.1	21.9	19.3	17.2	17.2
ROE ROE%	22.2	26.7	21.7	20.1	22.8	23.2	14.7	12.5	18.1	15.8	12.5	12.5
ROA ROA%	6.5	9.2	7.8	6.5	10.6	10.7	7.7	6.7	10.2	9.8	8.7	8.7
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

	PLATIND	VIKRAMTH	SUNSHIEL	AMNPLST	AMAL	CHEMCON	TRANSPEK
Market CapitalizationMkt CapCr	1,253	1,200	917	882	836	793	781
Close PriceClose₹	228.06	382.65	1,043.10	160.39	676.40	216.56	1,397.90
IndustryIndustry	Specialty Chemicals	Specialty Chemicals	Specialty Chemicals	Specialty Chemicals	Specialty Chemicals	Specialty Chemicals	Specialty Chemicals
Price To EarningsPE	24.84	27.35	24.19	22.88	28.05	28.16	20.03
Price To SalesPS	2.82	8.32	2.02	1.52	2.28	3.14	1.26
RevenueRevenueCr	444	144	455	581	366	253	618
Revenue Growth TTMRev Gr TTM%	9.6%	16.7%	13.1%	-12.4%	96.8%	17.4%	-5.2%
PAT Growth TTMPAT Gr TTM%	10.2%	42.3%	108.7%	-3.0%	-23.1%	10.6%	-29.1%

	PLATIND	VIKRAMTH	SUNSHIEL	AMNPLST	AMAL	CHEMCON	TRANSPEK
Market CapitalizationMkt CapCr	1,253	1,200	917	882	836	793	781
Close PriceClose₹	228.06	382.65	1,043.10	160.39	676.40	216.56	1,397.90
IndustryIndustry	Specialty Chemicals	Specialty Chemicals	Specialty Chemicals	Specialty Chemicals	Specialty Chemicals	Specialty Chemicals	Specialty Chemicals
Price To EarningsPE	24.84	27.35	24.19	22.88	28.05	28.16	20.03
Price To SalesPS	2.82	8.32	2.02	1.52	2.28	3.14	1.26
RevenueRevenueCr	444	144	455	581	366	253	618
Revenue Growth TTMRev Gr TTM%	9.6%	16.7%	13.1%	-12.4%	96.8%	17.4%	-5.2%
PAT Growth TTMPAT Gr TTM%	10.2%	42.3%	108.7%	-3.0%	-23.1%	10.6%	-29.1%

FY2026

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2026

Jun 26

Result PPT

Transcript

Summary

Mar 26